AstraZeneca PLC may soon be most recognized as an oncology company. The UK pharma's oncology portfolio is its dominant growth driver and will soon edge out the other two business units – cardiovascular/metabolic and respiratory – in terms of revenue contribution.
AstraZeneca's Oncology Business Delivers, Edging Toward CV/Metabolic As Top Contributor
The fast-growing oncology business represented 29% of AstraZeneca's second quarter sales, fueled by 44% revenue growth, outpacing sales of respiratory drugs and narrowing the gap with CV/metabolic.
